Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administe...
Akeso, Inc. is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Admi...
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, reported its consolidated financial results for the fourth quarter and full year ...
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant...
Pfizer Inc. announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)...
Interim analysis of data from the Phase III E.mbrace study (clinical trial identifier: NCT04899336), conducted by an independent data monitoring committee,...
SpringWorks Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced that the U.S. Food ...
Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) ...
Novartis announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceut...
GC Biopharma, a South Korean biopharmaceutical company, announced that it presented development updates on its LSD (lysosomal storage disorder) pipelines a...
Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced a corporate restr...
Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment o...
Bristol Myers Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with rel...
Global biotechnology leader CSL announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one...
© 2025 Biopharma Boardroom. All Rights Reserved.
